BioPharma Resources

Drug Trial Radar · NCT02618577

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes

Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET

Last checked: Nov 19, 2026Latest source record: Feb 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,608 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

2,608

Actual

Start

Feb 2016

Primary completion

Dec 31, 2022

Study completion Dec 31, 2022

Sponsor

Lead sponsor
Atrial Fibrillation NetworkAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company; Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)
First posted
Dec 1, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NOAH is an investigator-initiated, prospective, parallel-group, double-blind, randomised, multi-centre trial. The objective of the trial is to demonstrate that oral anticoagulation using the NOAC edoxaban is superior to current therapy to pre-vent stroke, systemic embolism, or cardiovascular death in patients with AHRE and at least two stroke risk factors but without AF. The trial will be conducted in several European countries.

Conditions

  • Atrial High Rate Episodes

Interventions

  • EdoxabanDrug

    Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF

  • ASADrug

    ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripheral or coronary artery disease, a prior myocardial infarction, or a prior stroke.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of Stroke, Systemic Embolism, or Cardiovascular DeathTime frame: 28 months

Locations

18 sites in 18 countries. Site status is shown where the registry gives one.

  • Several Sites

    Multiple Locations, Austria

  • Several Sites

    Multiple Locations, Belgium

  • Several

    Multiple Locations, Bulgaria

  • Several

    Multiple Locations, Czechia

  • Several

    Multiple Locations, Denmark

  • Several

    Multiple Locations, France

  • Several Sites

    Multiple Locations, Germany

  • Several

    Multiple Locations, Greece

  • Several

    Multiple Locations, Hungary

  • Several

    Multiple Locations, Italy

  • Several

    Multiple Locations, Netherlands

  • Several

    Multiple Locations, Poland

  • Several

    Multiple Locations, Portugal

  • Several

    Multiple Locations, Romania

  • Several

    Multiple Locations, Spain

  • Several

    Multiple Locations, Sweden

  • Several

    Multiple Locations, Ukraine

  • Several

    Multiple Locations, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.